Full Text View
Tabular View
No Study Results Posted
Related Studies
Medication Review in Patients on Anti-Parkinson Therapy (PDCom)
This study is enrolling participants by invitation only.
First Received: March 2, 2007   Last Updated: June 13, 2008   History of Changes
Sponsored by: South Glasgow University Hospitals NHS Trust
Information provided by: South Glasgow University Hospitals NHS Trust
ClinicalTrials.gov Identifier: NCT00443768
  Purpose

To identify patients within the community taking anti-parkinson medications in whom the diagnosis of Parkinson's disease is incorrect and to supervise and clinically monitor the withdrawal of anti-parkinson medications in this patient group


Condition
Parkinson's Disease

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease
MedlinePlus related topics: Parkinson's Disease
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Medication Review in Patients on Anti-Parkinson Therapy

Further study details as provided by South Glasgow University Hospitals NHS Trust:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 120
Study Start Date: October 2006
Estimated Study Completion Date: August 2008
Estimated Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
2

Detailed Description:

Step 1 - Practice based pharmacist and medical review using database search for the following:

  • Anti-parkinson drug therapy (excluding anticholinergic monotherapy).
  • Disease codes to identify Parkinson's disease and parkinsonism, and exclude other diagnoses where anti-parkinson therapy may be used, although both are expected to be very small numbers (pituitary tumour, restless leg syndrome)
  • To identify the duration of parkinsonism from the date of entry of the disease code.
  • Pharmacy re-fill data to identify intermittent usage of treatment as an indicator of it being unlikely that the patient has idiopathic or dopa responsive parkinsonism.
  • To identify patients on monotherapy with anti-parkinson therapy e.g. Selegiline for a prolonged duration as this is likely to suggest an alternative diagnosis.
  • To record drug dosage over time, e.g. on an annual basis, again to identify whether patients fit in with the expected rates of change for degenerative parkinsonism where increasing combinations of drugs at higher doses are used over time.

Step 2 - Review of case records:

  • Parkinson's disease nurse specialist and medical review of case records to identify additional clinical features of the condition and assist in identifying cases where it appears likely that anti-parkinson drug treatment is not helping the patient's condition.

Step 3 - Specialist out-patient review and follow-up:

  • Invitation to the patient to attend the combined neurology/medicine for the elderly movement disorder clinic service where scoring against diagnostic clinical criteria would be undertaken, and where appropriate tapering of anti-parkinson therapy gradually under continued specialist observation.
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Community sample of Parkinson's disease patients

Criteria

Inclusion Criteria:

Patients on anti-parkinson medication who:

  • Have been on monotherapy for a prolonged period, or
  • Use anti-parkinson medications intermittently, or
  • Do not have the expected change in medication over time in keeping with degenerative Parkinson's disease.

Exclusion Criteria:

  • Patients on anti-parkinson medication for reasons other than Parkinson's disease.
  • Patients with significant co-morbidity (end stage liver, cardiac or renal disease).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00443768

Locations
United Kingdom, Scotland
Southern General Hospital
Glasgow, Scotland, United Kingdom, G51 4TF
Sponsors and Collaborators
South Glasgow University Hospitals NHS Trust
Investigators
Study Chair: Donald Grosset, MD Dept of Neurology, INS, Southern General Hospital
Principal Investigator: Edward Newman, MRCP Dept of Neurology, INS, Southern General Hospital
  More Information

No publications provided

Responsible Party: Southern General Hospital ( Dr. D.Grosset )
Study ID Numbers: R060112/SW
Study First Received: March 2, 2007
Last Updated: June 13, 2008
ClinicalTrials.gov Identifier: NCT00443768     History of Changes
Health Authority: Scotland: Scottish Executive Health Department

Keywords provided by South Glasgow University Hospitals NHS Trust:
Medication
Diagnosis
Community

Study placed in the following topic categories:
Ganglion Cysts
Movement Disorders
Parkinson Disease
Basal Ganglia Diseases
Central Nervous System Diseases
Parkinsonian Disorders
Neurodegenerative Diseases
Brain Diseases

Additional relevant MeSH terms:
Movement Disorders
Parkinson Disease
Nervous System Diseases
Basal Ganglia Diseases
Central Nervous System Diseases
Parkinsonian Disorders
Neurodegenerative Diseases
Brain Diseases

ClinicalTrials.gov processed this record on May 07, 2009